Valeant Pharmaceuticals Intl Inc news

   Watch this stock
Showing stories 1 - 10 of about 208   

Articles published

VRX 10.86 +0.15 (1.45%)
price chart
Has Valeant Pharmaceuticals Intl Inc. Hit the Bottom?
Just when you thought Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) couldn't take any more bad news, billionaire investor William Ackman finally sold off the entire stake of Valeant last week at a nearly US$3 billion loss.
Stock Update (NYSE:VRX): Valeant Pharmaceuticals Intl Inc Completes ...  Smarter Analyst
Valeant Completes Refinancing Transactions  PR Newswire (press release)
Valeant Pharmaceuticals International Inc's declining sales show turnaround ...
The drugmaker reported a sharp drop in sales last quarter, and still has US$30 billion in debt hanging over its balance sheet that can only be dealt with by selling assets or improving cash flow.
Are We Witnessing the Resurgence of Valeant Pharmaceuticals Intl Inc.?  The Motley Fool Canada
Valeant predicts tough 2017 with revenue to decline  The Globe and Mail
William Ackman's Pershing Square sells entire position of Valeant ...
BOSTON - Billionaire investor William Ackman walked away from Valeant Pharmaceuticals International Inc on Monday with a roughly US$3 billion loss after he sold his entire stake in the ailing drug company after trying to rescue it for some 18 months.
Bill Ackman Throws in the Towel on Valeant Pharmaceuticals Intl Inc.  The Motley Fool Canada
Bill Ackman Is Out Of Valeant  Benzinga
Why Shares of Valeant Pharmaceuticals Intl Inc. Plunged Yet Again
The news release this week from Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) was more of the same and a reminder of the state of affairs at this company that was once riding high.
Valeant Announces Pricing And Upsize Of Private Offering Of Senior Secured Notes  Canada NewsWire (press release)
Valeant Pharmaceuticals Intl Inc (VRX): Too Many Reasons For Investors To ...  Smarter Analyst
Another Cut for Valeant Pharmaceuticals Intl Inc.
With another earnings release in the rear-view mirror, shares of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) have declined once again, this time to under $18 per share.
Rodman & Renshaw Cuts Price Target on Valeant Pharmaceuticals Intl Inc ...  Smarter Analyst
Should You Get Rid of Valeant Pharmaceuticals International (VRX) Now?  Yahoo Finance
Hedge Fund Manager Ken Griffin Winds Back on Valeant Pharmaceuticals Intl Inc ...
Hedge fund founder of Citadel Ken Griffin did not stake his claim as the wealthiest man in Illinois, by Forbes' reckoning, without playing it smart.
Valeant Announces the Early Results of Tender Offers for Its 6.75% Senior ...
LAVAL, Quebec, March 20, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") announced today that as of 5:00 p.m.
Valeant CEO Joseph Papa made $62.7 million last year
Valeant Pharmaceuticals International Inc. Chief Executive Joseph Papa received compensation last year valued at $62.7 million, after the drug-industry veteran was tapped to take over the struggling drug company suffering from accounting problems, high ...
Why Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Only Getting Worse
Glycyx PharmaVentures and Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Agree To ...
Glycyx PharmaVentures a development and biopharma investment company started by Lorin K. Johnson, Ph.D and Valeant Pharmaceuticals Intl Inc (NYSE:VRX) plan to enter into an exclusive license agreement under which Valeant will license Glycyx to ...
Valeant Pharmaceuticals Completes Sale Of CeraVe, AcneFree And AMBI Skincare ...
LAVAL, Quebec, March 3, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that it has completed the previously announced sale of its CeraVe, AcneFree and AMBI skincare brands to L'Or�al ...
Company Update (NYSE:VRX): Valeant Pharmaceuticals Intl Inc Completes Sale ...  Smarter Analyst
Valeant: Probably Worthless, Or Risky But Attractive Now?  Seeking Alpha